Sucampo Pharmaceuticals (SCMP) Cut to Buy at BidaskClub

BidaskClub lowered shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.

SCMP has been the subject of a number of other research reports. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective for the company in a research report on Tuesday, October 17th. Mizuho lifted their price objective on shares of Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a neutral rating in a research report on Friday, December 8th. Nomura started coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a buy rating and a $43.00 price objective for the company. ValuEngine raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, December 1st. Finally, started coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a buy rating and a $14.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $20.25.

Sucampo Pharmaceuticals (SCMP) opened at $18.00 on Wednesday. The firm has a market cap of $839.46, a price-to-earnings ratio of -5.37, a P/E/G ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.75. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

In other news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.13% of the company’s stock.

Several hedge funds have recently made changes to their positions in SCMP. JPMorgan Chase & Co. bought a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $117,000. Trexquant Investment LP bought a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth about $122,000. Nine Chapters Capital Management LLC bought a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth about $127,000. Stifel Financial Corp bought a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $131,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth about $132,000. 67.09% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was first published by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://weekherald.com/2018/02/17/sucampo-pharmaceuticals-scmp-cut-to-buy-at-bidaskclub.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply